A citation-based method for searching scientific literature

Vikas S Sridhar, Lisa Dubrofsky, Jacinthe Boulet, David Z Cherney. J Bras Nefrol 2020
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

The physiological role of glucagon-like peptide-1 in the regulation of renal function.
Lívia X S Farah, Vanessa Valentini, Thaissa D Pessoa, Gerhard Malnic, Alicia A McDonough, Adriana C C Girardi. Am J Physiol Renal Physiol 2016
53
50

Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
JingWei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L Neuen, Clare Arnott, Roger Simpson, Richard Oh, Kenneth W Mahaffey, Hiddo J L Heerspink. Kidney Int 2020
15
50

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Johannes F E Mann, Roland E Schmieder, Matthew McQueen, Leanne Dyal, Helmut Schumacher, Janice Pogue, Xingyu Wang, Aldo Maggioni, Andrzej Budaj, Suphachai Chaithiraphan,[...]. Lancet 2008
50

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Fengxia Xiao, Joseph Zimpelmann, Hans-Juergen Woerle, Odd E Johansen, Uli C Broedl, Maximilian von Eynatten, Kevin D Burns. Kidney Int 2014
79
50

β-Hydroxybutyrate: A signaling metabolite in starvation response?
Pedro Rojas-Morales, Edilia Tapia, José Pedraza-Chaverri. Cell Signal 2016
59
50

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
David Z I Cherney, Claire C J Dekkers, Sean J Barbour, Daniel Cattran, Abdul Halim Abdul Gafor, Peter J Greasley, Gozewijn D Laverman, Soo Kun Lim, Gian Luca Di Tanna, Heather N Reich,[...]. Lancet Diabetes Endocrinol 2020
51
50

Novel therapies for diabetic kidney disease.
David Z I Cherney, George L Bakris. Kidney Int Suppl (2011) 2018
20
50

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
Renato O Crajoinas, Felipe T Oricchio, Thaissa D Pessoa, Bruna P M Pacheco, Lucília M A Lessa, Gerhard Malnic, Adriana C C Girardi. Am J Physiol Renal Physiol 2011
150
50

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
242
50

Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.
Thaissa Dantas Pessoa, Luciene Cristina Gastalho Campos, Luciene Carraro-Lacroix, Adriana C C Girardi, Gerhard Malnic. J Am Soc Nephrol 2014
89
50

Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.
David Z I Cherney, Darren K McGuire, Bernard Charbonnel, Francesco Cosentino, Richard Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong,[...]. Circulation 2021
7
50

The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature.
Zachary Belden, Jeffrey A Deiuliis, Mirela Dobre, Sanjay Rajagopalan. Am J Nephrol 2017
29
50


Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Maria Ida Maiorino, Paolo Chiodini, Giuseppe Bellastella, Annalisa Capuano, Katherine Esposito, Dario Giugliano. Diabetes Care 2017
58
50


Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Linda F Fried, Nicholas Emanuele, Jane H Zhang, Mary Brophy, Todd A Conner, William Duckworth, David J Leehey, Peter A McCullough, Theresa O'Connor, Paul M Palevsky,[...]. N Engl J Med 2013
638
50

Cardiorenal syndrome type 4: management.
Anna Clementi, Grazia Maria Virzì, Alessandra Brocca, Massimo de Cal, Giorgio Vescovo, Antonio Granata, Claudio Ronco. Blood Purif 2013
12
50



SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
Soravis Osataphan, Chiara Macchi, Garima Singhal, Jeremy Chimene-Weiss, Vicencia Sales, Chisayo Kozuka, Jonathan M Dreyfuss, Hui Pan, Yanin Tangcharoenpaisan, Jordan Morningstar,[...]. JCI Insight 2019
59
50

Insulin resistance and heart failure: molecular mechanisms.
Annayya R Aroor, Chirag H Mandavia, James R Sowers. Heart Fail Clin 2012
106
50


GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
401
50

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Bernhard Ludvik, Juan P Frías, Francisco J Tinahones, Julio Wainstein, Honghua Jiang, Kenneth E Robertson, Luis-Emilio García-Pérez, D Bradley Woodward, Zvonko Milicevic. Lancet Diabetes Endocrinol 2018
112
50

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
R Kodera, K Shikata, H U Kataoka, T Takatsuka, S Miyamoto, M Sasaki, N Kajitani, S Nishishita, K Sarai, D Hirota,[...]. Diabetologia 2011
233
50

Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review.
Lisa Dubrofsky, Anand Srivastava, David Z Cherney. Can J Kidney Health Dis 2020
4
50

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, Anne Pernille Ofstad, Martina Brueckmann, Waheed Jamal,[...]. Circulation 2021
49
50

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Pardeep S Jhund, Scott D Solomon, Kieran F Docherty, Hiddo J L Heerspink, Inder S Anand, Michael Böhm, Vijay Chopra, Rudolf A de Boer, Akshay S Desai, Junbo Ge,[...]. Circulation 2021
48
50

High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
Hiroyuki Umino, Kazuhiro Hasegawa, Hitoshi Minakuchi, Hirokazu Muraoka, Takahisa Kawaguchi, Takeshi Kanda, Hirobumi Tokuyama, Shu Wakino, Hiroshi Itoh. Sci Rep 2018
58
50

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.
P Schlatter, C Beglinger, J Drewe, H Gutmann. Regul Pept 2007
102
50


Macrophage biology in development, homeostasis and disease.
Thomas A Wynn, Ajay Chawla, Jeffrey W Pollard. Nature 2013
50

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Apostolos Tsapas, Ioannis Avgerinos, Thomas Karagiannis, Konstantinos Malandris, Apostolos Manolopoulos, Panagiotis Andreadis, Aris Liakos, David R Matthews, Eleni Bekiari. Ann Intern Med 2020
43
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

Renal physiology of glucose handling and therapeutic implications.
David Z Cherney, Mehmet Kanbay, Julie A Lovshin. Nephrol Dial Transplant 2020
19
50

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
95
50

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Bernard Zinman, Vaishali Bhosekar, Robert Busch, Ingrid Holst, Bernhard Ludvik, Desirée Thielke, James Thrasher, Vincent Woo, Athena Philis-Tsimikas. Lancet Diabetes Endocrinol 2019
81
50



Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
J Skov, M Pedersen, J J Holst, B Madsen, J P Goetze, S Rittig, T Jonassen, J Frøkiaer, A Dejgaard, J S Christiansen. Diabetes Obes Metab 2016
67
50

The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.
Lazaros A Nikolaidis, Anthony Sturzu, Carol Stolarski, Dariush Elahi, You-Tang Shen, Richard P Shannon. Cardiovasc Res 2004
119
50


Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney. Kidney Int 2018
127
50

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides,[...]. N Engl J Med 2012
779
50

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
50

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.
Jeppe Skov, Anders Dejgaard, Jørgen Frøkiær, Jens Juul Holst, Thomas Jonassen, Søren Rittig, Jens Sandahl Christiansen. J Clin Endocrinol Metab 2013
114
50

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
323
50

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Lindsay E Clegg, Robert C Penland, Srinivas Bachina, David W Boulton, Marcus Thuresson, Hiddo J L Heerspink, Stephanie Gustavson, C David Sjöström, James A Ruggles, Adrian F Hernandez,[...]. Cardiovasc Diabetol 2019
21
50

Aldosterone and cardiac fibrosis: in vitro studies.
M J Fullerton, J W Funder. Cardiovasc Res 1994
99
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.